[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360863-105":59,"doc-detail-360863-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cost-effectiveness-analysis-of-the-treatment-pathway-after-trastuzumab-treatment-failure-in-patients-with-her2-positive-advanced-breast-cancer-a-chinese-health-system-perspective","Cost-effectiveness analysis of the treatment pathway after trastuzumab treatment failure in patients with HER2-positive advanced breast cancer - a chinese health system perspective","","Objectives: Evaluate the relative cost-effectiveness of four treatment approaches for HER2-positive advanced breast cancer in the Chinese healthcare system after trastuzumab treatment failure, aligning with CSCO-recommended regimens including lapatinib plus capecitabine, pyrotinib plus capecitabine, trastuzumab emtansine (T-DM1), and trastuzumab deruxtecan (T-DXd). Methods: Reconstruct and extrapolate survival from clinical trials using FP, Royston–Parmar, and parametric models; run a partitioned survival model with a 3-week cycle and 10-year horizon, estimating costs, outcomes, and ICERs. Robustness: one-way and probabilistic sensitivity analyses.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cost-effectiveness-analysis-of-the-treatment-pathway-after-trastuzumab-treatment-failure-in-patients-with-her2-positive-advanced-breast-cancer-a-chinese-health-system-perspective/360863/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cost-effectiveness-analysis-of-the-treatment-pathway-after-trastuzumab-treatment-failure-in-patients-with-her2-positive-advanced-breast-cancer-a-chinese-health-system-perspective/360863.png","ImageObject",300,407,{"name":92,"@type":93},"Fans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study address after trastuzumab treatment failure?","Question",{"text":112,"@type":113},"The study evaluates the relative cost-effectiveness of four HER2-positive advanced breast cancer treatment pathways in the Chinese healthcare system after failure of trastuzumab-based treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which treatment options were compared in the cost-effectiveness analysis?",{"text":117,"@type":113},"The analysis compares lapatinib plus capecitabine with three alternatives: pyrotinib plus capecitabine, trastuzumab emtansine (T-DM1), and trastuzumab deruxtecan (T-DXd).",{"name":119,"@type":110,"acceptedAnswer":120},"How were survival outcomes and costs modeled?",{"text":121,"@type":113},"Survival data were reconstructed and extrapolated using fractional polynomial models, Royston–Parmar models, and standard parametric models, then synthesized in a partitioned survival model with a 3-week cycle over a 10-year horizon to estimate costs, health outcomes, and ICERs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360863,1790194098,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Zhou et al. BMC Health Services Research (2026) 26:939 BMC Health Services Research  \n[https://doi.org/10.1186/s12913-026-14618-8](https://doi.org/10.1186/s12913-026-14618-8)  \nRESEARCH Open Access  \nCost-effectiveness analysis of the treatment pathway after trastuzumab treatment failure in patients with HER2-positive advanced breast cancer: a chinese health system perspective  \nTianqi Zhou1†, Yu Zhang1†, Chenlu Li2, Nan Wu1, Zhixian Liu1, Jifu Wei1*, Ning Cai1* and Silu Xu1*  \nAbstract  \nObjectives Breast cancer stands out as a prevalent and life-threatening cancer among women, ranking as the second leading cause of cancer-related fatalities globally. Trastuzumab is a commonly employed treatment for human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer. Following trastuzumab treatment failure, the Chinese Society of Clinical Oncology (CSCO) recommends lapatinib with capecitabine, pyrotinib plus capecitabine, trastuzumab emtansine (T-DM1), and trastuzumab deruxtecan (T-DXd) . The study aimed to evaluate the relative cost-effectiveness of four treatment approaches for advanced breast cancer with HER2 positive status in the Chinese healthcare system.  \nMethods The clinical data for this study were acquired from the following clinical trials: NCT02422199, NCT03080805, NCT00829166, and NCT03529110 . Survival data were reconstructed and extrapolated using fractional polynomial (FP) models, Royston–Parmar (RP) models, and standard parametric models. A partitioned survival model with a 3-week cycle length and a 10-year time horizon was developed to estimate costs, health outcomes, and incremental cost-effectiveness ratios (ICERs) . The robustness of the model was tested using one-way sensitivity analysis and probabilistic sensitivity analysis.  \nResults The ICER values for pyrotinib plus capecitabine, T-DM1, and T-DXd were $59,278 . 37/QALY, $50,029 . 87/QALY, and $148,234 . 68/QALY, respectively, when compared to lapatinib plus capecitabine. The deterministic sensitivity analysis indicated that ICER variability was primarily driven by drug costs, patient body weight, hazard ratios (HRs) for  \n†Tianqi Zhou andYu Zhang contributed equally to this work.  \n*Correspondence: Jifu Wei [weijifu@njmu.edu.cn](weijifu@njmu.edu.cn)[ ](weijifu@njmu.edu.cn)Ning Cai [48783623@qq.com](48783623@qq.com)[ ](48783623@qq.com)Silu Xu [siluxu@njmu.edu.cn](siluxu@njmu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nZhou et al. BMC Health Services Research (2026) 26:939 Page 2 of 14  \nprogression-free survival (PFS) and overall survival (OS), and the utilities of the progression-free (PF) and progressive disease (PD) health states. A probabilistic sensitivity analysis revealed that lapatinib’s advantage produced a stable result at the willing-to-pay (WTP) threshold.  \nConcl","cbCaimVN4Lbb9d4a","https://ap.wps.com/l/cbCaimVN4Lbb9d4a","pdf",2061947,14,"English","# Abstract\n# Objectives\n# Methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What question does the study address after trastuzumab treatment failure?\",\"answer\":\"The study evaluates the relative cost-effectiveness of four HER2-positive advanced breast cancer treatment pathways in the Chinese healthcare system after failure of trastuzumab-based treatment.\"},{\"question\":\"Which treatment options were compared in the cost-effectiveness analysis?\",\"answer\":\"The analysis compares lapatinib plus capecitabine with three alternatives: pyrotinib plus capecitabine, trastuzumab emtansine (T-DM1), and trastuzumab deruxtecan (T-DXd).\"},{\"question\":\"How were survival outcomes and costs modeled?\",\"answer\":\"Survival data were reconstructed and extrapolated using fractional polynomial models, Royston–Parmar models, and standard parametric models, then synthesized in a partitioned survival model with a 3-week cycle over a 10-year horizon to estimate costs, health outcomes, and ICERs.\"}]","Cost-effectiveness analysis of the treatment pathway after trastuzumab treatment failure in patients with HER2-positive advanced breast cancer - a chinese health system perspective | PDF",1790141853,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bdbf14fd4a542cbe763552f1d5da8c0f.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7750665b9735947f79ade8046caf4176.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4f4f70fa23f764d4aba0c42b2c62456.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c472782eaf5ad9b09522e1c9d423754b.webp",980,1306]